Search

Displaying results 5021 - 5030 of 10000 in total
  1. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588]. … is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC))[L30428] and aims to induce broad T-cell

  2. Drug

    Eldecalcitol

    go.drugbank.com/drugs/DB05295
    Investigational

    Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis.

    Synonyms: 1α,25-dihydroxy-2β-(3-hydroxypropoxy)cholecalciferolCategories: Vitamin D and Analogues
  3. Drug

    Lisavanbulin

    go.drugbank.com/drugs/DB15224
    Investigational

    Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  4. Drug

    Giripladib

    go.drugbank.com/drugs/DB15426
    Investigational

    Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).

  5. Drug

    Imalumab

    go.drugbank.com/drugs/DB15558
    Investigational

    Imalumab is under investigation in clinical trial NCT02540356 (Phase 1/2a Two-arm Dose-escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer).

  6. Drug

    Porphobilinogen

    go.drugbank.com/drugs/DB02272
    Experimental

    Porphobilinogen is a pyrrole involved in porphyrin metabolism. It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propionic acid
  7. Drug

    Licofelone

    go.drugbank.com/drugs/DB04725
    Experimental

    It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. … Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  8. Drug

    Oxymetazoline

    go.drugbank.com/drugs/DB00935
    ApprovedInvestigational

    Oxymetazoline is an imidazole derivative and a potent, direct-acting alpha (α)-adrenergic agonist with affinity to both α<sub>1</sub>- and α<sub>2</sub>-adrenoceptors. … [A215542] Oxymetazoline is available in various formulations with a wide variety of clinical implications. The topical formulation of the drug is used to treat persistent facial redness in adults.

    Synonyms: 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol, 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolineMixtures: N-S-4
  9. Drug

    Escitalopram

    go.drugbank.com/drugs/DB01175
    ApprovedInvestigational

    Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. … that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.

    Synonyms: (S)-Citalopram, S(+)-CitalopramCategories: Monoamine Oxidase A Substrates, P-glycoprotein substrates
  10. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

    Categories: MATE 2-K Inhibitors, MATE 1 Inhibitors